Radiosensitizing drugs: Lessons to be learned from the oxaliplatin story

Journal of Clinical Oncology

Volumn 28, Issue 29, 2010, Pages

  Flatmark, Kjersti ^a   Ree, Anne Hansen ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; FLUOROPYRIMIDINE; FLUOROURACIL; OXALIPLATIN; RADIOSENSITIZING AGENT; VORINOSTAT;

CANCER CELL CULTURE; CHEMORADIOTHERAPY; CLINICAL ASSESSMENT; COLORECTAL CARCINOMA; DRUG EFFICACY; DRUG POTENTIATION; DRUG TREATMENT FAILURE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LETTER; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIOSENSITIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CANCER; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; ORGANOPLATINUM COMPOUNDS; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 79951922140     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.0921     Document Type: Letter

References (11)

1. Gerard JP, Azria D, Gourgou-Bourgade S, et al: Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: Results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 28:1638-1644, 2010
2. Blackstock AW, Hess S, Chaney S, et al: Oxaliplatin: In vitro evidence of its radiation sensitizing activity - Preclinical observations relevant to clinical trials. Int J Radiat Oncol Biol Phys 45:253s-254s, 1999 (suppl; abstr 202)
3. Midgley RS, Yanagisawa Y, Kerr DJ: Evolution of nonsurgical therapy for colorectal cancer. Nat Clin Pract Gastroenterol Hepatol 6:108-120, 2009
4. Seiwert TY, Salama JK, Vokes EE: The concurrent chemoradiation paradigm: General principles. Nat Clin Pract Oncol 4:86-100, 2007 (Pubitemid 46189538)
5. Folkvord S, Flatmark K, Seierstad T, et al: Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: Does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity? Radiother Oncol 86:428-434, 2008
6. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006 (Pubitemid 43209104)
7. Willett CG, Duda DG, di Tomaso E, et al: Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: A multidisciplinary phase II study. J Clin Oncol 27:3020-3026, 2009
8. Folkvord S, Ree AH, Furre T, et al: Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status. Int J Radiat Oncol Biol Phys 74:546-552, 2009
9. Ree AH, Dueland S, Folkvord S, et al: Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: The Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol 11:459-464, 2010
10. Di Gennaro E, Bruzzese F, Pepe S, et al: Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed. Cancer Biol Ther 8:782-791, 2009
11. Freyer G, Bossard N, Romestaing P, et al: Addition of oxaliplatin to continuous fluorouracil, l-folinic acid, and concomitant radiotherapy in rectal cancer: The Lyon R 97-03 phase I trial. J Clin Oncol 19:2433-2438, 2001 (Pubitemid 32391214)